View Past PerformanceThis company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsPhaseBio Pharmaceuticals バランスシートの健全性財務の健全性 基準チェック /06PhaseBio Pharmaceuticalsの健全性を判断するにはデータが不十分です主要情報n/a負債資本比率n/a負債インタレスト・カバレッジ・レシオn/a現金n/aエクイティn/a負債合計n/a総資産n/a財務の健全性に関する最新情報お知らせ • Aug 16PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filingOn 08/15/2024, PhaseBio Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 18PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filingOn 05/16/2024, PhaseBio Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 15Amended Disclosure Statement Conditionally Approved for PhaseBio Pharmaceuticals, Inc.The US Bankruptcy Court conditionally approved the modified first amended plan and disclosure statement of PhaseBio Pharmaceuticals, Inc. on May 13, 2024. The debtor had filed its amended disclosure statement in the Court on May 13, 2024. May 13, 2024 has been fixed as voting record date. The deadline to vote on the plan and the plan objection deadline is June 17, 2024. The confirmation hearing for the plan has been scheduled for June 26, 2024.お知らせ • Apr 03PhaseBio Pharmaceuticals, Inc. announced delayed annual 10-K filingOn 04/02/2024, PhaseBio Pharmaceuticals, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 17PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filingOn 11/15/2023, PhaseBio Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 26PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filingOn 08/25/2023, PhaseBio Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.すべての更新を表示Recent updatesお知らせ • Aug 16PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filingOn 08/15/2024, PhaseBio Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 18PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filingOn 05/16/2024, PhaseBio Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 15Amended Disclosure Statement Conditionally Approved for PhaseBio Pharmaceuticals, Inc.The US Bankruptcy Court conditionally approved the modified first amended plan and disclosure statement of PhaseBio Pharmaceuticals, Inc. on May 13, 2024. The debtor had filed its amended disclosure statement in the Court on May 13, 2024. May 13, 2024 has been fixed as voting record date. The deadline to vote on the plan and the plan objection deadline is June 17, 2024. The confirmation hearing for the plan has been scheduled for June 26, 2024.お知らせ • Apr 03PhaseBio Pharmaceuticals, Inc. announced delayed annual 10-K filingOn 04/02/2024, PhaseBio Pharmaceuticals, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 17PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filingOn 11/15/2023, PhaseBio Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 26PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filingOn 08/25/2023, PhaseBio Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 17PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filingOn 05/16/2023, PhaseBio Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jan 18Chiesi Farmaceutici S.p.A. completed the acquisition of all of the assets of PhaseBio Pharmaceuticals, Inc. primarily related to bentracimab.Chiesi Farmaceutici S.p.A. entered into an agreement to acquire all of the assets of PhaseBio Pharmaceuticals, Inc. primarily related to bentracimab for $100 million on November 4, 2022. As per the terms of the transaction, $40 million in cash to be paid at the closing of the Transaction (subject to adjustment), plus future contingent payments of up to $60 million (the “Milestone Payments”) in cash upon the completion of certain regulatory milestone events. Chiesi is required to deposit $4 million (the “Deposit Funds”) with an escrow agent within three business days after the execution of the Agreement, which amount will be credited against the purchase price payable by Chiesi upon the closing of the Transaction. PhaseBio will be required to pay Chiesi a break-up fee of $2 million. The Transaction, and the designation of Chiesi as the stalking horse bidder, is subject to the approval of the Bankruptcy Court. The completion of the Transaction is subject to a number of customary conditions, including that a specified number of required employees shall have accepted and not rescinded offers of employment or engagement as a consultant or independent contractor with Chiesi and any waiting period applicable to the transaction under any Antitrust Law shall have expired or been terminated. As of January 5, 2023, the transaction has received the approval from the bankruptcy court. Christian E. Plaza of Cooley LLP acted as legal advisor to PhaseBio. Heyward D. Armstrong and Justin G. Truesdale of Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P. and A. Lee Hogewood III and John R. Gardner of K&L Gates LLP both acted as legal advisors to Chiesi. Chiesi Farmaceutici S.p.A. completed the acquisition of all of the assets of PhaseBio Pharmaceuticals, Inc. primarily related to bentracimab on January 17, 2023.Price Target Changed • Sep 28Price target increased to US$18.00Up from US$14.33, the current price target is an average from 5 analysts. New target price is 6,904% above last closing price of US$0.26. Stock is down 92% over the past year. The company is forecast to post a net loss per share of US$1.22 next year compared to a net loss per share of US$2.98 last year.Major Estimate Revision • Aug 19Consensus revenue estimates fall by 68%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from US$9.47m to US$3.06m. Forecast losses increased from -US$1.07 to -US$1.22 per share. Biotechs industry in the US expected to see average net income decline 57% next year. Consensus price target of US$13.67 unchanged from last update. Share price fell 5.0% to US$1.13 over the past week.Seeking Alpha • Aug 12PhaseBio Pharmaceuticals GAAP EPS of -$0.34 misses by $0.03, revenue of $0.21M misses by $0.29MPhaseBio Pharmaceuticals press release (NASDAQ:PHAS): Q2 GAAP EPS of -$0.34 misses by $0.03. Revenue of $0.21M (-98.0% Y/Y) misses by $0.29M. Shares -0.86% PM.Major Estimate Revision • May 23Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$14.7m to US$9.47m. EPS estimate increased from -US$2.03 to -US$1.07 per share. Biotechs industry in the US expected to see average net income decline 52% next year. Consensus price target of US$14.33 unchanged from last update. Share price fell 13% to US$0.81 over the past week.Price Target Changed • Apr 27Price target decreased to US$14.33Down from US$16.00, the current price target is an average from 5 analysts. New target price is 1,191% above last closing price of US$1.11. Stock is down 64% over the past year. The company is forecast to post a net loss per share of US$2.03 next year compared to a net loss per share of US$2.98 last year.Price Target Changed • Dec 16Price target increased to US$16.00Up from US$14.00, the current price target is an average from 5 analysts. New target price is 599% above last closing price of US$2.29. Stock is down 47% over the past year. The company is forecast to post a net loss per share of US$2.65 next year compared to a net loss per share of US$3.39 last year.Recent Insider Transactions Derivative • Nov 11Independent Director exercised options to buy US$116k worth of stock.On the 8th of November, Nancy Hutson exercised options to buy 34k shares at a strike price of around US$2.49, costing a total of US$84k. This transaction amounted to 844% of their direct individual holding at the time of the trade. Since March 2021, Nancy's direct individual holding has increased from 1.00k shares to 4.00k. Company insiders have collectively bought US$224k more than they sold, via options and on-market transactions, in the last 12 months.Executive Departure • Sep 16Independent Director Peter Klein has left the companyOn the 14th of September, Peter Klein's tenure as Independent Director ended after 11.8 years in the role. As of June 2021, Peter still personally held only 2.30k shares (US$8.6k worth at the time). Peter is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 4.33 years.Major Estimate Revision • Aug 19Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast increased from US$5.08m to US$10.8m. EPS estimate fell from -US$2.31 to -US$2.56 per share. Biotechs industry in the US expected to see average net income decline 21% next year. Consensus price target of US$14.33 unchanged from last update. Share price fell 9.3% to US$3.03 over the past week.分析記事 • Aug 10PhaseBio Pharmaceuticals (NASDAQ:PHAS) Has Debt But No Earnings; Should You Worry?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Major Estimate Revision • Jun 19Consensus revenue estimates increase to US$4.07mThe consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$67.2k to US$4.07m. Forecast losses expected to reduce from -US$2.41 to -US$2.31 per share. Biotechs industry in the US expected to see average net income decline 5.1% next year. Consensus price target down from US$14.00 to US$12.75. Share price was steady at US$3.75 over the past week.Price Target Changed • Jun 19Price target decreased to US$12.75Down from US$14.00, the current price target is an average from 5 analysts. New target price is 240% above last closing price of US$3.75. Stock is down 26% over the past year.Major Estimate Revision • May 20Consensus EPS estimates increase to -US$2.31The consensus outlook for earnings per share (EPS) in 2021 has improved. 2021 revenue forecast increased from US$76.8k to US$84.0k. EPS estimate increased from -US$2.74 to -US$2.31. Biotechs industry in the US expected to see average net income decline 6.3% next year. Consensus price target of US$14.00 unchanged from last update. Share price rose 14% to US$3.19 over the past week.Major Estimate Revision • Mar 23Consensus revenue estimates fall to US$76.8kThe consensus outlook for revenues in 2021 has deteriorated. 2021 revenue forecast decreased from US$353.2k to US$76.8k. Forecast losses increased from -US$2.44 to -US$2.74 per share. Biotechs industry in the US expected to see average net income growth of 4.2% next year. Consensus price target up from US$13.50 to US$15.00. Share price fell 3.2% to US$3.88 over the past week.Price Target Changed • Mar 19Price target increased to US$15.00Up from US$13.50, the current price target is an average from 5 analysts. New target price is 287% above last closing price of US$3.88. Stock is up 34% over the past year.Reported Earnings • Mar 17Full year 2020 earnings released: US$3.39 loss per share (vs US$1.43 loss in FY 2019)Full year 2020 results: Net loss: US$98.6m (loss widened 151% from FY 2019). Products in clinical trials Phase II: 1 Phase III: 1分析記事 • Mar 04What Kind Of Shareholders Hold The Majority In PhaseBio Pharmaceuticals, Inc.'s (NASDAQ:PHAS) Shares?A look at the shareholders of PhaseBio Pharmaceuticals, Inc. ( NASDAQ:PHAS ) can tell us which group is most powerful...Is New 90 Day High Low • Feb 09New 90-day high: US$4.45The company is up 30% from its price of US$3.41 on 10 November 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 25% over the same period.分析記事 • Jan 08If You Had Bought PhaseBio Pharmaceuticals' (NASDAQ:PHAS) Shares A Year Ago You Would Be Down 28%This week we saw the PhaseBio Pharmaceuticals, Inc. ( NASDAQ:PHAS ) share price climb by 21%. But that doesn't change...Price Target Changed • Jan 07Price target lowered to US$13.50Down from US$14.75, the current price target is an average from 5 analysts. The new target price is 263% above the current share price of US$3.72. As of last close, the stock is down 32% over the past year.Is New 90 Day High Low • Dec 16New 90-day high: US$4.44The company is up 27% from its price of US$3.49 on 16 September 2020. The American market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Dec 01New 90-day high: US$3.80The company is up 2.0% from its price of US$3.72 on 01 September 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Major Estimate Revision • Nov 26Analysts lower revenue estimates to US$296.0kThe 2020 consensus revenue estimate decreased from US$375.0k. Earnings per share (EPS) also decreased, with analysts lowering their estimates from -US$2.95 to -US$3.02 for the same period. The Biotechs industry in the US is expected to see an average net income growth of 7.0% next year. The consensus price target of US$14.25 was unchanged from the last update. Share price is up 3.4% to US$3.69 over the past week.Major Estimate Revision • Nov 19Analysts lower revenue estimates to US$375.0kThe 2020 consensus revenue estimate decreased from US$538.0k. Earnings per share (EPS) also decreased, with analysts lowering their estimates from -US$2.95 to -US$3.08 for the same period. The Biotechs industry in the US is expected to see an average net income growth of 6.5% next year. The consensus price target of US$14.25 was unchanged from the last update. Share price is down by 2.7% to US$3.57 over the past week.Analyst Estimate Surprise Post Earnings • Nov 14Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 100%. Earnings per share (EPS) exceeded analyst estimates by 21%. Over the next year, revenue is expected to shrink by 73% compared to a 397% growth forecast for the Biotechs industry in the US.Is New 90 Day High Low • Oct 24New 90-day low: US$3.10The company is down 34% from its price of US$4.68 on 24 July 2020. The American market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.財務状況分析短期負債: PHAS.Qの 短期資産 が 短期負債 をカバーしているかどうかを判断するにはデータが不十分です。長期負債: PHAS.Qの短期資産が 長期負債 をカバーしているかどうかを判断するにはデータが不十分です。デット・ツー・エクイティの歴史と分析負債レベル: PHAS.Qの 純負債対資本比率 を計算して 満足できる ものであるかどうかを判断するにはデータが不十分です。負債の削減: PHAS.Qの負債対資本比率が過去 5 年間で減少したかどうかを判断するにはデータが不十分です。債務返済能力: PHAS.Qの負債が 営業キャッシュフロー によって 十分にカバーされている かどうかを判断するにはデータが不十分です。インタレストカバレッジ: PHAS.Qの負債に対する 利息支払い が EBIT によって 十分にカバーされている かどうかを判断するにはデータが不十分です。貸借対照表健全な企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/09/12 22:19終値2024/09/12 00:00収益2022/06/30年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋PhaseBio Pharmaceuticals, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Andrew FeinH.C. Wainwright & Co.Chad MesserNeedham & CompanyAnnabel SamimyStifel, Equities Research2 その他のアナリストを表示
お知らせ • Aug 16PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filingOn 08/15/2024, PhaseBio Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 18PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filingOn 05/16/2024, PhaseBio Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 15Amended Disclosure Statement Conditionally Approved for PhaseBio Pharmaceuticals, Inc.The US Bankruptcy Court conditionally approved the modified first amended plan and disclosure statement of PhaseBio Pharmaceuticals, Inc. on May 13, 2024. The debtor had filed its amended disclosure statement in the Court on May 13, 2024. May 13, 2024 has been fixed as voting record date. The deadline to vote on the plan and the plan objection deadline is June 17, 2024. The confirmation hearing for the plan has been scheduled for June 26, 2024.
お知らせ • Apr 03PhaseBio Pharmaceuticals, Inc. announced delayed annual 10-K filingOn 04/02/2024, PhaseBio Pharmaceuticals, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 17PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filingOn 11/15/2023, PhaseBio Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 26PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filingOn 08/25/2023, PhaseBio Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 16PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filingOn 08/15/2024, PhaseBio Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 18PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filingOn 05/16/2024, PhaseBio Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 15Amended Disclosure Statement Conditionally Approved for PhaseBio Pharmaceuticals, Inc.The US Bankruptcy Court conditionally approved the modified first amended plan and disclosure statement of PhaseBio Pharmaceuticals, Inc. on May 13, 2024. The debtor had filed its amended disclosure statement in the Court on May 13, 2024. May 13, 2024 has been fixed as voting record date. The deadline to vote on the plan and the plan objection deadline is June 17, 2024. The confirmation hearing for the plan has been scheduled for June 26, 2024.
お知らせ • Apr 03PhaseBio Pharmaceuticals, Inc. announced delayed annual 10-K filingOn 04/02/2024, PhaseBio Pharmaceuticals, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 17PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filingOn 11/15/2023, PhaseBio Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 26PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filingOn 08/25/2023, PhaseBio Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 17PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filingOn 05/16/2023, PhaseBio Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jan 18Chiesi Farmaceutici S.p.A. completed the acquisition of all of the assets of PhaseBio Pharmaceuticals, Inc. primarily related to bentracimab.Chiesi Farmaceutici S.p.A. entered into an agreement to acquire all of the assets of PhaseBio Pharmaceuticals, Inc. primarily related to bentracimab for $100 million on November 4, 2022. As per the terms of the transaction, $40 million in cash to be paid at the closing of the Transaction (subject to adjustment), plus future contingent payments of up to $60 million (the “Milestone Payments”) in cash upon the completion of certain regulatory milestone events. Chiesi is required to deposit $4 million (the “Deposit Funds”) with an escrow agent within three business days after the execution of the Agreement, which amount will be credited against the purchase price payable by Chiesi upon the closing of the Transaction. PhaseBio will be required to pay Chiesi a break-up fee of $2 million. The Transaction, and the designation of Chiesi as the stalking horse bidder, is subject to the approval of the Bankruptcy Court. The completion of the Transaction is subject to a number of customary conditions, including that a specified number of required employees shall have accepted and not rescinded offers of employment or engagement as a consultant or independent contractor with Chiesi and any waiting period applicable to the transaction under any Antitrust Law shall have expired or been terminated. As of January 5, 2023, the transaction has received the approval from the bankruptcy court. Christian E. Plaza of Cooley LLP acted as legal advisor to PhaseBio. Heyward D. Armstrong and Justin G. Truesdale of Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P. and A. Lee Hogewood III and John R. Gardner of K&L Gates LLP both acted as legal advisors to Chiesi. Chiesi Farmaceutici S.p.A. completed the acquisition of all of the assets of PhaseBio Pharmaceuticals, Inc. primarily related to bentracimab on January 17, 2023.
Price Target Changed • Sep 28Price target increased to US$18.00Up from US$14.33, the current price target is an average from 5 analysts. New target price is 6,904% above last closing price of US$0.26. Stock is down 92% over the past year. The company is forecast to post a net loss per share of US$1.22 next year compared to a net loss per share of US$2.98 last year.
Major Estimate Revision • Aug 19Consensus revenue estimates fall by 68%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from US$9.47m to US$3.06m. Forecast losses increased from -US$1.07 to -US$1.22 per share. Biotechs industry in the US expected to see average net income decline 57% next year. Consensus price target of US$13.67 unchanged from last update. Share price fell 5.0% to US$1.13 over the past week.
Seeking Alpha • Aug 12PhaseBio Pharmaceuticals GAAP EPS of -$0.34 misses by $0.03, revenue of $0.21M misses by $0.29MPhaseBio Pharmaceuticals press release (NASDAQ:PHAS): Q2 GAAP EPS of -$0.34 misses by $0.03. Revenue of $0.21M (-98.0% Y/Y) misses by $0.29M. Shares -0.86% PM.
Major Estimate Revision • May 23Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$14.7m to US$9.47m. EPS estimate increased from -US$2.03 to -US$1.07 per share. Biotechs industry in the US expected to see average net income decline 52% next year. Consensus price target of US$14.33 unchanged from last update. Share price fell 13% to US$0.81 over the past week.
Price Target Changed • Apr 27Price target decreased to US$14.33Down from US$16.00, the current price target is an average from 5 analysts. New target price is 1,191% above last closing price of US$1.11. Stock is down 64% over the past year. The company is forecast to post a net loss per share of US$2.03 next year compared to a net loss per share of US$2.98 last year.
Price Target Changed • Dec 16Price target increased to US$16.00Up from US$14.00, the current price target is an average from 5 analysts. New target price is 599% above last closing price of US$2.29. Stock is down 47% over the past year. The company is forecast to post a net loss per share of US$2.65 next year compared to a net loss per share of US$3.39 last year.
Recent Insider Transactions Derivative • Nov 11Independent Director exercised options to buy US$116k worth of stock.On the 8th of November, Nancy Hutson exercised options to buy 34k shares at a strike price of around US$2.49, costing a total of US$84k. This transaction amounted to 844% of their direct individual holding at the time of the trade. Since March 2021, Nancy's direct individual holding has increased from 1.00k shares to 4.00k. Company insiders have collectively bought US$224k more than they sold, via options and on-market transactions, in the last 12 months.
Executive Departure • Sep 16Independent Director Peter Klein has left the companyOn the 14th of September, Peter Klein's tenure as Independent Director ended after 11.8 years in the role. As of June 2021, Peter still personally held only 2.30k shares (US$8.6k worth at the time). Peter is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 4.33 years.
Major Estimate Revision • Aug 19Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast increased from US$5.08m to US$10.8m. EPS estimate fell from -US$2.31 to -US$2.56 per share. Biotechs industry in the US expected to see average net income decline 21% next year. Consensus price target of US$14.33 unchanged from last update. Share price fell 9.3% to US$3.03 over the past week.
分析記事 • Aug 10PhaseBio Pharmaceuticals (NASDAQ:PHAS) Has Debt But No Earnings; Should You Worry?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Major Estimate Revision • Jun 19Consensus revenue estimates increase to US$4.07mThe consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$67.2k to US$4.07m. Forecast losses expected to reduce from -US$2.41 to -US$2.31 per share. Biotechs industry in the US expected to see average net income decline 5.1% next year. Consensus price target down from US$14.00 to US$12.75. Share price was steady at US$3.75 over the past week.
Price Target Changed • Jun 19Price target decreased to US$12.75Down from US$14.00, the current price target is an average from 5 analysts. New target price is 240% above last closing price of US$3.75. Stock is down 26% over the past year.
Major Estimate Revision • May 20Consensus EPS estimates increase to -US$2.31The consensus outlook for earnings per share (EPS) in 2021 has improved. 2021 revenue forecast increased from US$76.8k to US$84.0k. EPS estimate increased from -US$2.74 to -US$2.31. Biotechs industry in the US expected to see average net income decline 6.3% next year. Consensus price target of US$14.00 unchanged from last update. Share price rose 14% to US$3.19 over the past week.
Major Estimate Revision • Mar 23Consensus revenue estimates fall to US$76.8kThe consensus outlook for revenues in 2021 has deteriorated. 2021 revenue forecast decreased from US$353.2k to US$76.8k. Forecast losses increased from -US$2.44 to -US$2.74 per share. Biotechs industry in the US expected to see average net income growth of 4.2% next year. Consensus price target up from US$13.50 to US$15.00. Share price fell 3.2% to US$3.88 over the past week.
Price Target Changed • Mar 19Price target increased to US$15.00Up from US$13.50, the current price target is an average from 5 analysts. New target price is 287% above last closing price of US$3.88. Stock is up 34% over the past year.
Reported Earnings • Mar 17Full year 2020 earnings released: US$3.39 loss per share (vs US$1.43 loss in FY 2019)Full year 2020 results: Net loss: US$98.6m (loss widened 151% from FY 2019). Products in clinical trials Phase II: 1 Phase III: 1
分析記事 • Mar 04What Kind Of Shareholders Hold The Majority In PhaseBio Pharmaceuticals, Inc.'s (NASDAQ:PHAS) Shares?A look at the shareholders of PhaseBio Pharmaceuticals, Inc. ( NASDAQ:PHAS ) can tell us which group is most powerful...
Is New 90 Day High Low • Feb 09New 90-day high: US$4.45The company is up 30% from its price of US$3.41 on 10 November 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 25% over the same period.
分析記事 • Jan 08If You Had Bought PhaseBio Pharmaceuticals' (NASDAQ:PHAS) Shares A Year Ago You Would Be Down 28%This week we saw the PhaseBio Pharmaceuticals, Inc. ( NASDAQ:PHAS ) share price climb by 21%. But that doesn't change...
Price Target Changed • Jan 07Price target lowered to US$13.50Down from US$14.75, the current price target is an average from 5 analysts. The new target price is 263% above the current share price of US$3.72. As of last close, the stock is down 32% over the past year.
Is New 90 Day High Low • Dec 16New 90-day high: US$4.44The company is up 27% from its price of US$3.49 on 16 September 2020. The American market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Dec 01New 90-day high: US$3.80The company is up 2.0% from its price of US$3.72 on 01 September 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Major Estimate Revision • Nov 26Analysts lower revenue estimates to US$296.0kThe 2020 consensus revenue estimate decreased from US$375.0k. Earnings per share (EPS) also decreased, with analysts lowering their estimates from -US$2.95 to -US$3.02 for the same period. The Biotechs industry in the US is expected to see an average net income growth of 7.0% next year. The consensus price target of US$14.25 was unchanged from the last update. Share price is up 3.4% to US$3.69 over the past week.
Major Estimate Revision • Nov 19Analysts lower revenue estimates to US$375.0kThe 2020 consensus revenue estimate decreased from US$538.0k. Earnings per share (EPS) also decreased, with analysts lowering their estimates from -US$2.95 to -US$3.08 for the same period. The Biotechs industry in the US is expected to see an average net income growth of 6.5% next year. The consensus price target of US$14.25 was unchanged from the last update. Share price is down by 2.7% to US$3.57 over the past week.
Analyst Estimate Surprise Post Earnings • Nov 14Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 100%. Earnings per share (EPS) exceeded analyst estimates by 21%. Over the next year, revenue is expected to shrink by 73% compared to a 397% growth forecast for the Biotechs industry in the US.
Is New 90 Day High Low • Oct 24New 90-day low: US$3.10The company is down 34% from its price of US$4.68 on 24 July 2020. The American market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.